华西医学

华西医学

晚期不可手术切除胰腺癌治疗新进展

查看全文

胰腺癌是一种高度恶性肿瘤,占全世界新发癌症的3%,手术及全身化学疗法(化疗)为主要治疗手段。手术被认为是唯一可能治愈胰腺癌的手段,可切除胰腺癌预后较不可切除胰腺癌预后明显提高,5年生存率提高到20%以上;对于不可手术切除的胰腺癌,以吉西他滨为主的全身化疗已取代氟尿嘧啶成为晚期胰腺癌的标准治疗方案,但1年生存率仅为18%。目前转移性胰腺癌临床试验、JASPAC-01、CONKO-001等临床研究表明,吉西他滨联合白蛋白紫杉醇、替吉奥、厄洛替尼等治疗方案可取得临床获益,进一步延长中位生存期和中位无疾病进展生存期,但1年生存率并未见明显获益。晚期胰腺癌治疗是多种治疗方案的集合体,根据患者不同病程阶段制定个体化治疗方案,在循证证据下的个体化治疗方案将进一步得到重视,胰腺癌治疗将是在全身化疗基础上开展的个性化治疗。

关键词: 晚期胰腺癌; 全身化学疗法; 治疗

引用本文: 曹蓉, 李燕雏. 晚期不可手术切除胰腺癌治疗新进展. 华西医学, 2015, 30(8): 1577-1580. doi: 10.7507/1002-0179.20150452 复制

登录后 ,请手动点击刷新查看全文内容。 没有账号,
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015[J]. CA Cancer J Clin, 2015, 65(1):5-29.
2. Thota R, Pauff JM, Berlin JD. Treatment of metastatic pancreatic adenocarcinoma:a review[J]. Oncology (Williston Park), 2014, 28(1):70-74.
3. 李兆申. 胰腺癌早期诊断研究现状及展望[J]. 临床肝胆病杂志, 2010, 26(5):451-453.
4. 楼文辉. 局部晚期和转移性胰腺癌的综合治疗[J]. 上海医学, 2010, 33(11):992-994.
5. Vaccaro V, Sperduti I, Milella M. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer[J]. N Engl J Med, 2011, 365(8):768-769.
6. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer[J]. N Engl J Med, 2011, 364(19):1817-1825.
7. Zagouri F, Sergentanis TN, Chrysikos D, et al. Molecularly targeted therapies in metastatic pancreatic cancer:a systematic review[J]. Pancreas, 2013, 42(5):760-773.
8. Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection:a randomized controlled trial[J]. JAMA, 2010, 304(10):1073-1081.
9. Hartwig W, Werner J, Jäger D, et al. Improvement of surgical results for pancreatic cancer[J]. Lancet Oncol, 2013, 14(11):e476-e485.
10. Greenhalf W, Ghaneh P, Neoptolemos JP, et al. Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial[J]. J Natl Cancer Inst, 2014, 106(1):djt347.
11. Neoptolemos JP, Stocken DD, Tudur Smith C, et al. Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer:composite data from the ESPAC-1and -3(v1) trials[J]. Br J Cancer, 2009, 100(2):246-250.
12. Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer:the CONKO-001 randomized trial[J]. JAMA, 2013, 310(14):1473-1481.
13. Ueno H, Kosuge T, Matsuyama Y, et al. A randomised phase Ⅲ trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer:Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer[J]. Br J Cancer, 2009, 101(6):908-915.
14. Maeda A, Boku N, Fukutomi A, et al. Randomized phase Ⅲ trial of adjuvant chemotherapy with gemcitabine versus S-1 in patients with resected pancreatic cancer:Japan Adjuvant Study Group of Pancreatic Cancer (JASPAC-01)[J]. Jpn J Clin Oncol, 2008, 38(3):227-229.
15. Fukutomi A, Uesaka K, Boku N, et al. JASPAC 01:randomized phase Ⅲ trial of adjuvant chemotherapy with gemcitabine versus S-1 for patients with resected pancreatic cancer[C/OL]. 2013 ASCO Annual Meeting. http://meetinglibrary.asco.org/content/116237-132.
16. Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer:a randomized trial[J]. J Clin Oncol, 1997, 15(6):2403-2413.
17. Poplin E, Feng Y, Berlin J, et al. Phase Ⅲ, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201:a trial of the Eastern Cooperative Oncology Group[J]. J Clin Oncol, 2009, 27(23):3778-3785.
18. Cunningham D, Chau I, Stocken DD, et al. Phase Ⅲ randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer[J]. J Clin Oncol, 2009, 27(33):5513-5518.
19. Heinemann V, Quietzsch D, Gieseler F, et al. Randomized phase Ⅲ trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer[J]. J Clin Oncol, 2006, 24(24):3946-3952.
20. Colucci G, Labianca R, Di Costanzo F, et al. Randomized phase Ⅲ trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer:the GIP-1 study[J]. J Clin Oncol, 2010, 28(10):1645-1651.
21. Kindler HL, Friberg G, Singh DA, et al. Phase Ⅱ trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer[J]. J Clin Oncol, 2005, 23(31):8033-8040.
22. Kindler HL, Niedzwiecki D, Hollis D, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer:phase Ⅲ trial of the Cancer and Leukemia Group B (CALGB 80303)[J]. J Clin Oncol, 2010, 28(22):3617-3622.
23. Stathopoulos GP, Syrigos K, Aravantinos G, et al. A multicenter phase Ⅲ trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer[J]. Br J Cancer, 2006, 95(5):587-592.
24. Oettle H, Richards D, Ramanathan RK, et al. A phase Ⅲ trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer[J]. Ann Oncol, 2005, 16(10):1639-1645.
25. Philip PA, Benedetti J, Corless CL, et al. Phase Ⅲ study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma:Southwest Oncology Group-directed intergroup trial S0205[J]. J Clin Oncol, 2010, 28(22):3605-3610.
26. Kasuga A, Okano N, Naruge D, et al. Retrospective analysis of fixed dose rate infusion of gemcitabine and S-1 combination therapy (FGS) as salvage chemotherapy in patients with gemcitabine-refractory advanced pancreatic cancer:inflammation-based prognostic score predicts survival[J]. Cancer Chemother Pharmacol, 2015, 75(3):457-464.
27. Conroy T, Paillot B, François E, et al. Irinotecan plus oxaliplatin and leucovorin-modulated fluorouracil in advanced pancreatic cancer——a Groupe Tumeurs Digestives of the Federation Nationale des Centres de Lutte Contre le Cancer study[J]. J Clin Oncol, 2005, 23(6):1228-1236.
28. Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine[J]. N Engl J Med, 2013, 369(18):1691-1703.
29. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer:a phase Ⅲ trial of the National Cancer Institute of Canada Clinical Trials Group[J]. J Clin Oncol, 2007, 25(15):1960-1966.
30. Yang ZY, Yuan JQ, Di MY, et al. Gemcitabine plus erlotinib for advanced pancreatic cancer:a systematic review with meta-analysis[J]. PLoS One, 2013, 8(3):e57528.
31. Epstein AS, Abou-Alfa GK, Shamseddine A, et al. Communication and palliative care in a 64-year-old man with pancreatic adenocarcinoma[J]. Gastrointest Cancer Res, 2012, 5(4):130-134.
32. Middleton GW, Valle JW, Wadsley J, et al. A phase Ⅲ randomized trial of chemoimmunotherapy comprising gemcitabine and capecitabine with or without telomerase vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer[J]. J Clin Oncol, 2013, 31(18 Suppl):LBA4004.
33. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer[J]. N Engl J Med, 2010, 363(8):733-742.
34. MA Rodriguez, YA Dejesus, L Cheng, et al. Factors related to end-of-life (EOL) chemotherapy in solid tumor (ST) patients[J]. J Clin Oncol, 2013, 31(31):334-350.
35. Romanus D, Kindler HL, Archer L, et al. Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase Ⅲ trial of the cancer and leukemia group B (CALGB 80303)[J]. J Pain Symptom Manage, 2012, 43(2):205-217.
36. Li D, Morris JS, Liu J, et al. Body mass index and risk, age of onset, and survival in patients with pancreatic cancer[J]. JAMA, 2009, 301(24):2553-2562.
37. Greer JA, Pirl WF, Jackson VA, et al. Effect of early palliative care on chemotherapy use and end-of-life care in patients with metastatic non-small-cell lung cancer[J]. J Clin Oncol, 2012, 30(4):394-400.